Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | PTPRA | P18433 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29694017 | 1.00 | CYP1A2 (0.53) | CYP1A2FDPSPTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL9092131 | 1.00 | CYP1A2 (0.53) | CYP1A2FDPSPTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL7887713 | 0.86 | CYP1A2 (0.53) | CYP1A2FDPSPTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL27875620 | 0.86 | CYP1A2 (0.53) | CYP1A2FDPSPTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL7549451 | 0.84 | CYP1A2 (0.51) | CYP1A2FDPSPTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL8503990 | 0.83 | CYP1A2 (0.70) | CYP1A2PTPRASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL7886018 | 0.83 | CYP1A2 (0.50) | CYP1A2FDPSPTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL6638562 | 0.81 | FDPS (0.54) | CYP1A2FDPSPTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL8862654 | 0.81 | FDPS (0.47) | CYP1A2FDPSPTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL5820534 | 0.81 | FDPS (0.47) | CYP1A2FDPSPTPRASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101084227-A | Rapamycin analogs and their use for treating neurological disorders, proliferative and inflammatory diseases | WYETH CORP (US) | 2007-12-05 | — | — | CN | claimed |
| EP-0730598-B1 | HINDERED ESTERS OF RAPAMYCIN AND THEIR USE AS PHARMACEUTICALS | AMERICAN HOME PROD (US) | 1999-06-09 | — | — | EP | claimed |
| EP-0730598-A1 | HINDERED ESTERS OF RAPAMYCIN AND THEIR USE AS PHARMACEUTICALS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-11 | — | — | EP | claimed |
| WO-1995014696-A1 | HINDERED ESTERS OF RAPAMYCIN AND THEIR USE AS PHARMACEUTICALS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-06-01 | — | — | WO | claimed |
| US-5385908-A | Hindered esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | claimed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| EP-1828202-B1 | RAPAMCYIN ANALOGUES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PROLIFERATIVE AND INFLAMMATORY DISORDERS | WYETH LLC (US) | 2012-03-14 | — | — | EP | disclosed |
| CN-101084227-B | Rapamycin analogs and their use for treating neurological disorders, proliferative and inflammatory diseases | WYETH CORP | 2011-11-16 | — | — | CN | disclosed |
| US-7795252-B2 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders | PFIZER INC. (US) | 2010-09-14 | — | — | US | disclosed |
| CN-101626777-A | Immunophilin ligands and methods of modulating immunophilin and calcium channel activity | WYETH CORP | 2010-01-13 | — | — | CN | disclosed |
| US-20090239855-A1 | Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological, Proliferative, and Inflammatory Disorders | WYETH (US) | 2009-09-24 | — | — | US | disclosed |
| EP-1828202-A2 | RAPAMCYIN ANALOGUES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGIAL PROLIFERATIVE AND INFLAMMATORY DISORDERS | Wyeth a Corporation of the State of Delaware (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070142423-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders | WYETH (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2006068932-A2 | RAPAMYCIN ANALOGUES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PROLIFERATIVE, AND INFLAMMATORY DISORDERS | WYETH (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135549-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders | WYETH (US) | 2006-06-22 | — | — | US | disclosed |
| EP-0730598-B1 | HINDERED ESTERS OF RAPAMYCIN AND THEIR USE AS PHARMACEUTICALS | AMERICAN HOME PROD (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0730598-A1 | HINDERED ESTERS OF RAPAMYCIN AND THEIR USE AS PHARMACEUTICALS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014696-A1 | HINDERED ESTERS OF RAPAMYCIN AND THEIR USE AS PHARMACEUTICALS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-06-01 | — | — | WO | disclosed |
| US-5385908-A | Hindered esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142423-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders | RPTOR, MTOR, RICTOR | CYP1A2 4550/4885FDPS 2053/4885PTPRA 2011/4885 |
| US-20060135549-A1 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders | RPTOR, MTOR, RICTOR | CYP1A2 4550/4885FDPS 2053/4885PTPRA 2011/4885 |
| US-20090239855-A1 | Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological, Proliferative, and Inflammatory Disorders | BDNF, MTOR, RICTOR | CYP1A2 4777/4885FDPS 1315/4885PTPRA 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.